$USFD

US Foods Holding Corp. (USFD): Results of Operations and Financial Condition

US Foods Holding Corp. (USFD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 usfd06272026ex991.htm EX-99.1 Document Exhibit 99.1 INVESTOR CONTACT: MEDIA CONTACT: Mike Neese Sara Matheu (847) 232-5894 (773) 580-3775 Michael.Neese@usfoods.com Sara.Matheu@usfoods.com US Foods Reports Second Quarter Fiscal Year 2026 Earnings Grew Net Sales 4.5% to $

Original reporting
Published Aug 6, 2026, 10:47 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$USFD
Bullish
high confidence
Mentioned
$USFD
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$USFDBullishHigh
01

Why it matters

Traders can update models and expectations using the reported Q2 operating metrics, capital allocation (repurchases), leverage (net debt/EBITDA), and the reaffirmed FY2026 guidance ranges.

02

Market read

Q2 results and reaffirmed FY2026 guidance provide a direct catalyst for USFD positioning, with margin expansion and independent restaurant volume growth as key themes.

03

What to watch

Investors may discount non-GAAP performance and scrutinize the drivers of margin expansion (LIFO adjustment, cost productivity) for durability into the back half of FY2026.

Relevance 7/10Novelty 9/10Timing: filed pre-market today (Aug. 6, 2026) with Q2 results and FY2026 guidance reaffirmation

Background

This is an SEC Form 8-K (Item 2.02) with the company’s Q2 FY2026 earnings release and financial condition details.

Company-level read

Ticker impact

$USFDBullishHigh confidence
Context

US Foods reported Q2 FY2026 results with net sales up 4.5% to $10.5B, adjusted EBITDA up 10.2% to $604M, and reaffirmed FY2026 guidance.

Expected impact

Likely positive bias for the stock as investors weigh margin expansion, record adjusted EBITDA, and reaffirmed growth guidance.

Evidence & confidence

The filing includes multiple quantified beats versus the prior year (sales, net income, adjusted EBITDA, EPS) and reiterates FY2026 net sales, adjusted EBITDA, and adjusted EPS growth ranges, alongside active repurchases and stable leverage (2.6x).

Market effects

Foodservice distribution demand and margin trends are reinforced by independent restaurant case volume growth and cost productivity commentary.

Primarily US-focused foodservice distribution read-through for domestic consumer and restaurant activity.

Limited direct global impact; mostly relevant to US foodservice supply chain expectations.

Counterpoint

Despite strong adjusted metrics, the company still flags a “challenging but stable” industry, so the market may focus on sustainability of volume growth and food-cost inflation.

Key entities

  • US Foods Holding Corp.

    Reported Q2 FY2026 results, record adjusted EBITDA, share repurchases, and reaffirmed FY2026 guidance.

  • Dave Flitman

    CEO and Chair, cited accelerating volume growth and confidence in share gains and cash flow.

  • Dirk Locascio

    CFO, discussed margin expansion and capital allocation/leverage.

Related articles

$VRDNMed

Viridian Therapeutics, Inc.\DE (VRDN): Results of Operations and Financial Condition

Viridian Therapeutics, Inc.\DE (VRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d174744dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Lumvoa ™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PD

$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_ex991.htm EX-99.1 Document Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Confer

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria

$WBDMed

Warner Bros. Discovery, Inc. (WBD): Results of Operations and Financial Condition

Warner Bros. Discovery, Inc. (WBD) filed an SEC Form 8-K — Results of Operations and Financial Condition. disca-20260806 0001437107 false 0001437107 2026-08-06 2026-08-06 0001437107 us-gaap:CommonClassAMember 2026-08-06 2026-08-06 0001437107 disca:SeniorNotesDue20304.302Member 2026-08-06 2026-08-06 0001437107 disca:SeniorNotesDue20304.302AMember 2026-08-06 2026-08-06 0001437107 disca